7
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      International Journal of COPD (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on pathophysiological processes underlying Chronic Obstructive Pulmonary Disease (COPD) interventions, patient focused education, and self-management protocols. Sign up for email alerts here.

      39,063 Monthly downloads/views I 2.893 Impact Factor I 5.2 CiteScore I 1.16 Source Normalized Impact per Paper (SNIP) I 0.804 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Inhaled corticosteroids (ICS) are often more widely prescribed in the treatment of chronic obstructive pulmonary disease (COPD) than what is recommended in the guidelines. The aim of this study was to evaluate the appropriateness of ICS treatment in COPD patients using the algorithm proposed by the International Primary Care Respiratory Group (IPCRG) and to identify factors associated with ICS treatment.

          Patients and methods

          Appropriateness of ICS therapy was studied with respect to concomitant asthma, history of exacerbations and blood eosinophils (B-Eos) in a Swedish cohort of primary and secondary care patients with COPD. Factors associated with ICS were investigated using multivariable logistic regression.

          Results

          Triple treatment was found to be the most common treatment combination, used by 46% of the 561 included patients, and in total 63% were using ICS. When applying the IPCRG algorithm, there was a possible indication for discontinuation of ICS in 55% of the patients with ICS treatment. Of the patients not using ICS, 18% had an indication for starting such treatment. The strongest factors associated with ICS therapy were frequent exacerbations (aOR 8.61, 95% CI 4.06, 20.67), secondary care contacts (aOR 6.99, 95% CI 2.48, 25.28) and very severe airflow limitation (aOR 5.91, 95% CI 1.53, 26.58).

          Conclusion

          More than half of the COPD patients on ICS met the criteria where withdrawal of the treatment could be tried. There was, however, also a subgroup of patients not using ICS for whom there was an indication for starting ICS treatment. Patients using ICS were characterized by more frequent exacerbations and lower lung function.

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.

          The peripheral blood eosinophil count might help identify those patients with chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations when taking inhaled corticosteroids (ICS). Previous post-hoc analyses have proposed eosinophil cutoffs that are both arbitrary and limited in evaluating complex interactions of treatment response. We modelled eosinophil count as a continuous variable to determine the characteristics that determine both exacerbation risk and clinical response to ICS in patients with COPD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale.

            This study tested the hypothesis that severity of respiratory disability may affect the outcome of pulmonary rehabilitation. In this randomized, controlled study, 126 patients with chronic obstructive pulmonary disease (COPD) were stratified for dyspnoea using the Medical Research Council (MRC) dyspnoea score into MRC3/4 (Moderate) (n=66) and MRC 5 (Severe) dyspnoeic (n=60) groups. The patients were randomly assigned to an eight week programme of either exercise plus education (Exercise group) or education (Control group). Education and exercise programmes for the moderately dyspnoeic patients were carried out in a hospital outpatient setting. Severely dyspnoeic patients were all treated at home. Those in the Exercise group received an individualized training programme. There was a significant improvement in shuttle walking distance in the moderate dyspnoeic group, who received exercise training; baseline (mean+/-SEM) 191+/-22 m, post-rehabilitation 279+/-22 m (p<0.001). There was no improvement in exercise performance in the severely dyspnoeic patients receiving exercise. Neither group of control patients improved. Health status, assessed by the Total Chronic Respiratory Disease Questionnaire score, increased in the moderately dyspnoeic patients receiving exercise from 80+/-18 to 95+/-17 (p<0.0001) after rehabilitation. Much smaller changes were seen in the other three groups. Improvement in exercise performance and health status in patients with chronic obstructive pulmonary disease after an exercise programme depends on the initial degree of dyspnoea.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.

              Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD).
                Bookmark

                Author and article information

                Journal
                Int J Chron Obstruct Pulmon Dis
                Int J Chron Obstruct Pulmon Dis
                COPD
                copd
                International Journal of Chronic Obstructive Pulmonary Disease
                Dove
                1176-9106
                1178-2005
                05 November 2019
                2019
                : 14
                : 2451-2460
                Affiliations
                [1 ]Department of Pharmaceutical Biosciences, Uppsala University , Uppsala, Sweden
                [2 ]Centre for Research and Development, Uppsala University/Region Gävleborg , Gävle, Sweden
                [3 ]Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University , Uppsala, Sweden
                [4 ]Department of Medical Sciences, Clinical Pharmacogenomics and Osteoporosis, Uppsala University , Uppsala, Sweden
                [5 ]Department of Medical Sciences, Clinical Physiology, Uppsala University , Uppsala, Sweden
                [6 ]Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University , Uppsala, Sweden
                Author notes
                Correspondence: Johanna Sulku Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University , Box 591, UppsalaSE-751 24, SwedenTel +46 73 635 7075Fax +46 26 531 237 Email johanna.sulku@farmbio.uu.se
                Author information
                http://orcid.org/0000-0002-1444-752X
                http://orcid.org/0000-0001-5093-6980
                http://orcid.org/0000-0002-6857-5973
                http://orcid.org/0000-0002-4098-7765
                http://orcid.org/0000-0001-8497-7326
                http://orcid.org/0000-0002-0080-5023
                http://orcid.org/0000-0002-6392-6092
                http://orcid.org/0000-0002-3107-4462
                http://orcid.org/0000-0002-9181-1321
                http://orcid.org/0000-0003-0725-214X
                Article
                218747
                10.2147/COPD.S218747
                6842319
                31806954
                0548c07b-bdba-4c0b-9e99-06853ba03422
                © 2019 Sulku et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 08 June 2019
                : 23 September 2019
                Page count
                Figures: 3, Tables: 1, References: 31, Pages: 10
                Categories
                Original Research

                Respiratory medicine
                ics,pharmacological management,inappropriate therapy,chronic obstructive pulmonary disease,ipcrg

                Comments

                Comment on this article